Quoin Pharmaceuticals LtdNASDAQ:QNRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6088
- TODAY'S CHANGE (%)-0.0112 (-1.8065%)
- Bid / Lots0.6100/ 1
- Ask / Lots0.6200/ 4
- Open / Previous Close0.6480 / 0.6200
- Day Range
- 52 Week Range
- Volume91,883
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QNRX |
|---|---|---|
| 09:38 ET | 3160 | 0.65 |
| 09:39 ET | 900 | 0.65 |
| 09:41 ET | 200 | 0.65 |
| 09:45 ET | 1102 | 0.65 |
| 11:11 ET | 769 | 0.65 |
| 11:27 ET | 203 | 0.6399 |
| 11:44 ET | 200 | 0.6301 |
| 12:12 ET | 2800 | 0.63 |
| 12:39 ET | 200 | 0.62 |
| 12:48 ET | 280 | 0.63 |
| 12:56 ET | 206 | 0.619899 |
| 01:01 ET | 6106 | 0.6116 |
| 01:24 ET | 23176 | 0.6 |
| 01:30 ET | 1212 | 0.59 |
| 01:53 ET | 200 | 0.648 |
| 02:49 ET | 123 | 0.645999 |
| 02:54 ET | 1037 | 0.623 |
| 03:09 ET | 157 | 0.6 |
| 03:14 ET | 47250 | 0.6001 |
| 03:23 ET | 130 | 0.623 |
| 03:27 ET | 500 | 0.6455 |
| 03:59 ET | 162 | 0.6088 |
Jun 27, 2024
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome, from 8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Quoin Pharmaceuticals Ltd | 2.5M | -0.1x | --- |
Biophytis SA | 2.3M | -0.1x | --- |
Qrons Inc | 2.5M | -3.3x | --- |
Entero Therapeutics Inc | 2.4M | 0.0x | --- |
Tharimmune Inc | 2.4M | 0.0x | --- |
Kiromic Biopharma Inc | 2.3M | -0.1x | --- |
Company Information
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Contact Information
- Headquarters
- 23 Hata'as StreetKFAR SABA, Israel 44425
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Abraham Nahmias
- Director
- Shai Yarkoni
- Chief Financial Officer
- Eyal Leibovitz
- Chief Operating Officer, Vice President
- Amos Ofer
- Vice President - Research & Development & Product Development
- Amotz Nehushtan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.94 |
EPS | $-8.38 |
Book Value | $5.74 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
